NDAORALTABLET
Approved
Jul 2015
Lifecycle
Peak
Competitive Pressure
0/100
Clinical Trials
20
Data completeness
6/8 — Strong
REXULTI (brexpiprazole) by Otsuka is 12. Approved for atypical antipsychotic [epc]. First approved in 2015.
Drug data last refreshed 2d ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
REXULTI (brexpiprazole) is an atypical antipsychotic that functions as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and antagonist at 5-HT2A receptors. It is approved for adjunctive treatment of major depressive disorder, agitation associated with Alzheimer's dementia, and schizophrenia. The exact mechanism of efficacy remains incompletely understood, though multimodal monoaminergic activity is implicated.
$630MPart D
Peak6.8 years to LOEREXULTI is at peak commercial maturity with substantial Medicare Part D utilization, suggesting a stable, established brand team with focus on market share maintenance and managed care negotiations.
Mechanism of Action
12.1 Mechanism of Action The mechanism of action of REXULTI in the adjunctive treatment of major depressive disorder, treatment of agitation associated with dementia due to Alzheimer's disease, or treatment of schizophrenia is unknown. However, the efficacy of REXULTI may be mediated through a…
Worked on REXULTI at Otsuka? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.